SkyePharma says asthma treatment trials successful

LONDON, July 22 (Reuters) - British biotech company SkyePharma (SKP.L: Quote, Profile, Research) said it had successfully completed two European Phase III clinical studies for its asthma treatment Flutiform.

The first trial, undertaken by SkyePharma's marketing partner Mundipharma, found Flutiform's performance was not statistically inferior to that of GlaxoSmithKline (GSK.L: Quote, Profile, Research) treatment Seretide for 182 patients with mild to moderate-severe asthma, the company said on Tuesday .

The second trial, with involved 196 adult and adolescent patients suffering from mild to moderate-severe asthma, confirmed that Flutiform was not inferior to a course of its constituents fluticasone and formoterol, it said.

Chief Operating Officer Ken Cunningham said he was delighted that the company had two further Phase III studies for European regulatory submission that had met their endpoints. (Reporting by Paul Sandle; editing by Rory Channing)